GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Peptron Inc (XKRX:087010) » Definitions » Debt-to-Revenue

Peptron (XKRX:087010) Debt-to-Revenue : 4.77 (As of Mar. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Peptron Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Peptron's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₩4,590 Mil. Peptron's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₩4,520 Mil. Peptron's annualized Revenue for the quarter that ended in Mar. 2024 was ₩1,909 Mil. Peptron's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 was 4.77.


Peptron Debt-to-Revenue Historical Data

The historical data trend for Peptron's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Peptron Debt-to-Revenue Chart

Peptron Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 16.19 2.96 1.38 1.59 2.73

Peptron Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.98 3.30 3.35 2.86 4.77

Competitive Comparison of Peptron's Debt-to-Revenue

For the Biotechnology subindustry, Peptron's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Peptron's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Peptron's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Peptron's Debt-to-Revenue falls into.



Peptron Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Peptron's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(4606.89 + 4526.097) / 3341.894
=2.73

Peptron's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(4589.818 + 4519.571) / 1909.068
=4.77

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Mar. 2024) Revenue data.


Peptron Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Peptron's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Peptron (XKRX:087010) Business Description

Traded in Other Exchanges
N/A
Address
37-24, Yuseong-daero 1628 beon-gil, Yuseong-gu, Daejeon, KOR, 305811
Peptron Inc is a biotechnology company engaged in developing fundamental technologies for peptide-based medicines. Its technology includes PeptrEX and SmartDepot. PeptrEX is an automatic system, enabling to synthesize simultaneously from a few to hundred types of peptides. SmartDepot is a proprietary ultrasonic spray drying technology for the preparation of sustained release injectable microsphere formulation of the drug. The group's research and development products include Luphere Depot for the treatment of prostate cancer and endometriosis, SR Exenatide PT302 AND SR EXENATIDE PT304 for the treatment of type II diabetes, SR Exenatide PT320 and 330 for the treatment of Parkinson's and Alzheimer's disease and SR Octreotide for the treatment of acromegaly and carcinoid tumor.

Peptron (XKRX:087010) Headlines

No Headlines